Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep 8;2010(9):CD007696.
doi: 10.1002/14651858.CD007696.pub2.

Interventions for the treatment of borderline ovarian tumours

Olusola Faluyi  1 , Melanie Mackean, Charlie Gourley, Andrew Bryant, Heather O Dickinson
Affiliations

Interventions for the treatment of borderline ovarian tumours

Olusola Faluyi et al. Cochrane Database Syst Rev. .

Abstract

Background: The safety of conservative surgery and the benefit of additional interventions after surgery for borderline ovarian tumours are unknown.

Objectives: To evaluate the benefits and harm of different treatment modalities offered for borderline ovarian tumours.

Search strategy: We searched the Cochrane Gynaecological Cancer Group Trials Register to 2009, Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 4), MEDLINE and EMBASE to 2009. We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of included studies.

Selection criteria: Randomised controlled trials (RCTs) that compared different interventions in adult women diagnosed with borderline ovarian tumours of any histological variant.

Data collection and analysis: Two review authors independently abstracted data and assessed risk of bias.

Main results: We identified seven RCTs that enrolled 372 women. We could not pool results of trials as the treatment comparisons differed.Six RCTs (n = 340) conducted over 15 years ago, evaluated adjuvant therapy (chemotherapy, pelvic external irradiation or intra-peritoneal radioactive isotope therapy) after radical surgery; over 87% of participants had Stage I tumours. Most participants were followed up for over 10 years. Overall and recurrence-free survival were similar between both arms of these trials, except that one trial (n = 66) showed a significantly lower survival (P = 0.03) in women who received chemotherapy (thio-TEPA). Adverse effects of treatment were incompletely reported and all six trials were at high risk of bias.One further trial (n = 32) that recruited participants with bilateral serous tumours who were wishing fertility preservation, revealed a significantly increased chance of pregnancy (hazard ratio (HR) = 3.3, 95% CI 1.4 to 8.0) but non-significantly earlier disease recurrence (HR = 1.5, 95% CI 0.6 to 3.8) in the women who had ultra-conservative surgery (bilateral cystectomy) than in those who had conservative surgery (cystectomy and contralateral oophorectomy). This trial was at low risk of bias.Quality of life (QoL) was not documented in any included trial. We did not find any trials that compared radical with conservative surgery or laparoscopy with laparotomy.

Authors' conclusions: We did not find evidence to support the use of any specific type of adjuvant therapy for borderline ovarian tumours. RCTs evaluating the benefit of adjuvant therapy with optimally dosed chemotherapy and newer targeted drugs are necessary, particularly for advanced borderline ovarian tumours. The low mortality from borderline ovarian tumours should make recurrence-free survival, time to recurrence and morbidity important end points in such trials.Bilateral cystectomy may be offered to women with bilateral borderline ovarian tumours diagnosed intra-operatively who are wishing to preserve their fertility. Similarly, women who had RCTs comparing radical with conservative surgery and comparing laparoscopy with laparotomy are needed.

PubMed Disclaimer

Conflict of interest statement

None

Figures

1
1
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
2
2
Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD007696

References

References to studies included in this review

Creasman 1982 {published data only}
    1. Creasman WT, Park R, Norris H, Disaia PJ, Morrow CP, Hreshchyshyn MM. Stage I borderline ovarian tumors. Obstetrics and Gynecology 1982;59(1):93‐6. - PubMed
Palomba 2007 {published data only}
    1. Palomba S, Zupi E, Russo T, Falbo A, Negro S, Manguso F, et al. Comparison of two fertility‐sparing approaches for bilateral borderline ovarian tumours: a randomized controlled study. Human Reproduction 2007;22(2):578–85. - PubMed
Sutton 1991 {published data only}
    1. Sutton GP, Bundy BN, Omura GA, Yordan EL, Beecham JB, Bonfiglio T. Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study). Gynecologic Oncology 1991;41(3):230‐3. - PubMed
Trope 1993 (Study 1) {published data only}
    1. Kolstad P, Davy M, Høeg K. Individualised treatment of ovarian cancer. Journal of Obstetrics and Gynecology 1977;128:617‐25. - PubMed
    1. Trope C, Kaern J, Vergote IB, Kristensen G, Abeler V. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. [Review] [27 refs]. Gynecologic Oncology 1993;51(2):236‐43. - PubMed
Trope 1993 (Study 2) {published data only}
    1. Trope C, Kaern J, Vergote IB, Kristensen G, Abeler V. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. [Review] [27 refs]. Gynecologic Oncology 1993;51(2):236‐43. - PubMed
Trope 1993 (Study 3) {published data only}
    1. Trope C, Kaern J, Vergote IB, Kristensen G, Abeler V. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. [Review] [27 refs]. Gynecologic Oncology 1993;51(2):236‐43. - PubMed
Trope 1993 (Study 4) {published data only}
    1. Trope C, Kaern J, Vergote IB, Kristensen G, Abeler V. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. [Review] [27 refs]. Gynecologic Oncology 1993;51(2):236‐43. - PubMed

References to studies excluded from this review

Swanton 2007 {published data only}
    1. Swanton A, Bankhead CR, Kehoe S. Pregnancy rates after conservative treatment for borderline ovarian tumours: a systematic review. [Review] [36 refs]. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2007;135(1):3‐7. - PubMed
Vergote 1992 {published data only}
    1. Vergote IB, Vergote De Vos LN, Abeler VM, Aas M, Lindegaard MW, et al. Randomized trial comparing cisplatin with radioactive phosphorus or whole‐abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992; Vol. 69, issue 3:741‐9. - PubMed
Young 1990 {published data only}
    1. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. The New England Journal of Medicine 1990;322(15):1021‐7. - PubMed

Additional references

Abu‐Jawdeh 1996
    1. Abu‐Jawdeh, Jacobs TW, Niloff J, Cannistra SA. Estrogen receptor expression is a common feature of ovarian borderline tumors. Gynecologic Oncology 1996;60(2):301‐7. - PubMed
Altman 1995
    1. Altman DG, Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. British Journal of Cancer 1995;72:511‐8. - PMC - PubMed
Bell 1998
    1. Bell R, Petticrew M, Sheldon T. The performance of screening tests for ovarian cancer: results of a systematic review. British Journal of Obstetrics and Gynaecology 1998;105(11):1136‐47. - PubMed
Bostwick 1986
    1. Bostwick DG, Tazelaar HD, Ballon SC, Hendrickson MR, Kempson RL. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases. Cancer 1986;58(9):2052‐65. - PubMed
Bucher 1997
    1. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta‐analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683‐91. - PubMed
Cadron 2007
    1. Cadron I, Leunen K, Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. Journal of Clinical Oncology 2007;25(20):2928‐37. - PubMed
Chambers 1988
    1. Chambers JT, Merino MJ, Kohorn EI, Schwartz PE. Borderline ovarian tumors. American Journal of Obstetrics and Gynecology 1988;159(5):1088‐94. - PubMed
Chen 2002
    1. Chen VW, Ruiz B, Killeen JL, Coté TR, Wu XC, Correa CN. Pathology and classification of ovarian tumors. Cancer 2003;97 Suppl 10:2631‐42. - PubMed
Cochrane Handbook 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
CONSORT2010
    1. Schulz KF, Altman DG, Moher D. CONSORORT 2010 Statement: updated guidelines for reporting parallel group randomised trialsKenneth F. BMJ 2010;340:C332. - PMC - PubMed
Crispens 2002
    1. Crispens MA, Bodurka D, Deavers M, Lu K, Silva EG, Gershenson DM. Response and survival in patients with progressive or recurrent serous ovarian tumours of low malignant potential. Obstetrics and Gynecology 2002;99(1):3‐10. - PubMed
Crispens 2003
    1. Crispens MA. Borderline ovarian tumours: a review of the recent literature. Current Opinion in Obstetrics & Gynecology 2003;15(1):39‐43. - PubMed
CTCAE 2006
    1. CTCAE. Common Terminology Criteria for Adverse Events. (http://ctep.cancer.gov/forms/CTCAEv3.pdf) 9th August 2006; Vol. v3.0 (CTCAE).
Deeks 2001
    1. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: Egger M, Davey Smith G, Altman DG (editors). Systematic Reviews in Health Care: Meta‐Analysis in Context (2nd edition). . London: BMJ Publication Group, 2001.
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7:177‐88. - PubMed
Fauvet 2005
    1. Fauvet R, Poncelet C, Boccara J, Descamps P, Fondrinier E, Daraï E. Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study. Fertility and Sterility 2005;83(2):284‐90. - PubMed
FIGO 2006
    1. Benedet JL, Pecorelli S, Ngan HYS, Hacker NF (Editors). Staging Classifications and Clinical PracticeGuidelines for Gynaecological Cancers. FIGO website (http://www.figo.org/docs/staging_booklet.pdf) last accessed 18.08.2008 2006.
Firat 2003
    1. Firat S, Murray K, Erickson B. High‐dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long‐term toxicity and outcomes. International Journal of Radiation Oncology, Biology, Physics 2003;57(1):201‐207. - PubMed
Hart 2005
    1. Hart WR. Borderline epithelial tumors of the ovary. Modern Pathology 2005;18 Suppl 2:33‐50. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60. - PMC - PubMed
ICON 1 2003
    1. ICON 1. International collaborative ovarian neoplasm trial 1: A randomized trial of adjuvant chemotherapy in women with early‐stage ovarian cancer. Journal of the National Cancer Institute 2003;95(2):125‐32. - PubMed
ICON 2002
    1. ICON 2002. Paclitaxel plus carboplatin versus standard chemotherapy with either single‐agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:505‐15. - PubMed
Jemal 2008
    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer Statistics. CA: A Cancer Journal for Clinicians 2008;58:71‐96. - PubMed
Kurman 1993
    1. Kurman RJ, Trimble CL. The behavior of serous tumors of low malignant potential: are they ever malignant?. International Journal of Gynecological Pathology 1993;12(2):120‐27. - PubMed
Leake 1992
    1. Leake JF, Currie JL, Rosenshein NB, Woodruff JD. Long‐term follow‐up of serous ovarian tumors of low malignant potential. Gynecologic Oncology 1992;47(2):150‐8. - PubMed
Mackay 2008
    1. Mackay H, Hirte HW, Covens A, MacAlpine K, Wang L, Tsao MS, et al. A phase II trial of the histone deacetylase inhibitor belinostat (PXD 101) in patients with platinum resistant epithelial ovarian tumours and micro‐papillary/borderline (LMP) ovarian tumours. A PMH phase 2 consortium trial. Journal of Clinical Oncology 2008;26 Suppl:5518.
Menon 2009
    1. Menon U, Gentry‐Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncology 2009;10(4):327‐40. - PubMed
Mink 2002
    1. Mink PJ, Sherman ME, Devesa SS. Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Cancer 2002;95:2380‐9. - PubMed
Morrice 2001
    1. Morice P, Camatte S, Hassan J, Pautier P, Duvillard P, Castaigne D. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertility and Sterility 2001;75(1):92‐6. - PubMed
Muggia 2000
    1. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology group study. Journal of Clinical Oncology 2000;18(1):106‐15. - PubMed
Nakashima 1990
    1. Nakashima N, Nagasaka T, Oiwa N, Nara Y, Fukata S, Fukatsu T, et al. Ovarian epithelial tumors of borderline malignancy in Japan. Gynecologic Oncology 1990;38(1):90‐8. - PubMed
Odegaard 2007
    1. Ødegaard E, Staff AC, Langebrekke A, Engh V, Onsrud M. Surgery of borderline tumors of the ovary: retrospective comparison of short‐term outcome after laparoscopy or laparotomy. Acta Obstetricia et Gynaecologica Scandinavica 2007;86(5):620‐6. - PubMed
Palomba 2007
    1. Palomba S, Zupi E, Russo T, Falbo A, Negro S, Manguso F, et al. Comparison of two fertility‐sparing approaches for bilateral borderline ovarian tumours: a randomized controlled study. Human Reproduction 2007;22(2):578‐85. - PubMed
Palomba 2010
    1. Palomba S, Falbo A, Negro S, Rocca M, Russo T, Cariati F, Annunziata G, et al. Ultra‐conservative fertility‐sparing strategy for bilateral borderline ovarian tumours. Human Reproduction 2010; Vol. epub. - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34. - PubMed
Patridge 1996
    1. Partridge EE, Phillips JL, Menck HR. The National Cancer Data Base report on ovarian cancer treatment in United States hospitals. Cancer 1996;78(10):2236‐46. - PubMed
Prat 1999
    1. Prat J. Ovarian tumors of borderline malignancy (tumors of low malignant potential): a critical appraisal. Advances in Anatomical Pathology 1999;6(5):247‐74. - PubMed
Romagnolo 2006
    1. Romagnolo C, Gadducci A, Sartori E, Zola P, Maggino T. Management of borderline ovarian tumors: Results of an Italian multicenter study. Gynecologic Oncology 2006;101:255‐60. - PubMed
Silva 2006
    1. Silva EG, Gershenson DM, Malpica A, Deavers M. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. American Journal of Surgical Pathology 2006;30(11):1367‐71. - PubMed
Smyth 2007
    1. Smyth JF, Gourley C, Walker G, Mackean MJ, Stevenson A, Williams AR, et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor‐positive patients. Clinical Cancer Research 2007;13(12):3617‐22. - PubMed
Trimbos 2003
    1. Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. International Collaborative Ovarian Neoplasm 1, European Organisation for Research and Treatment of Cancer Collaborators ‐ Adjuvant chemotherapy in ovarian neoplasm. Impact of adjuvant chemotherapy and surgical staging in early‐stage ovarian carcinoma: European Organisation for Research and Treatment of cancer‐Adjuvant chemotherapy in ovarian neoplasm trial. Journal of the National Cancer Institute 2003;95(2):113‐25. - PubMed
Vernooij 2008
    1. Vernooij F, Heintz AP, Witteveen PO, Heiden‐van der Loo M, Coebergh JW, Graaf Y. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study. Journal of National Cancer Institute 2008;100(6):399‐406. - PubMed
WHO 2003
    1. Tavassoli FA, Develli P. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. WHO Press. 5. Lyon: IARC, 2003:117‐37.
Wong 2007
    1. Wong HF, Low JJ, Chua Y, Busmanis I, Tay EH, Ho TH. Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004. International Journal of Gynecologic Cancer 2007;17(2):342‐9. - PubMed

Publication types